Observational studyBMC endocrine disorders2026
Real-world experience with insulin glargine U300 in pediatric type 1 diabetes: glycemic control, insulin requirements, and patient-reported outcomes.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAchieving optimal glycemic control in children with type 1 diabetes(T1D) is challenging. Insulin glargine U300 offers a flatter pharmacodynamic profile and longer duration of action than glargine U100, but pediatric real-world data are limited. This study evaluated the effects of switching from U100 to U300 on glycemic control, body composition, pain, and quality of life.
methodsThis prospective, single-center observational study included children aged 6–20 years with T1D who switched from U100 to U300. Assessments were performed at baseline, week12, and week24. The primary endpoint was change in HbA1c; secondary endpoints included insulin dose(U/kg), hypoglycemia frequency, 3:00 a.m. glucose, lipid parameters, body composition, Numeric Rating Scale (NRS) for pain, and Pediatric Quality of Life Inventory (PedsQL) scores. Participants were stratified by baseline HbA1c (< 9% vs. ≥ 9%).
resultsSixty-three participants (mean age 14.98 ± 3.53 years) were analyzed. Basal insulin dose increased significantly from 0.48 ± 0.12 U/kg/day on Gla-100 to 0.51 ± 0.14 and 0.51 ± 0.15 U/kg/day at weeks 12 and 24, respectively (p < 0.001). HbA1c levels demonstrated a small but statistically significant change during follow-up (p = 0.048). (8.20 (5.9–14.8) %→ 8.00 (6.0–12.2) %→ 8.25 (5.7–12.6) %). Participants with HbA1c ≥ 9% showed a significant reduction(ΔHbA1c − 0.50 (− 3.80–1.00) %; p = 0.014), while those < 9% had a mild increase(ΔHbA1c 0.10 (− 0.90–5.30) %). Night-time (03:00 AM) blood glucose levels decreased significantly across the three time points (p = 0.007), more prominently in the higher HbA1c group. NRS improved markedly (p < 0.001), though PedsQL scores were unchanged.
conclusionsSwitching from U100 to U300 maintained glycemic control with modest insulin dose increases. Greater benefits were observed in patients with higher baseline HbA1c, alongside reduced nocturnal glucose and injection pain.U300 appears to enhance comfort and nighttime stability in pediatric T1D. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.